Comparison of ovarian stimulation results in ivf cycles given gonal f (follitropin alfa) and pergoveris (follitropin alfa and lutropin alfa)
Keywords:
OHSS, IVF, Gonal-f, , pergoveris, infertility patientsAbstract
The aim of this study is to compare the effect of adding lutropin alfa to follitropin alfa on treatment dose, duration, number of oocytes retrieved, number of embryos formed, number of live births, and ovarian hyperstimulation syndrome (OHSS) compared to follitropin alfa alone ingonadotropin therapy used for ovarian stimulation (OS) in in-vitro fertilization (IVF) cycles. The study comprised infertile women aged 20 to 44 years old who applied to Ondokuz Mays University Medical Faculty Hospital IVF Center between January and June 2021 who were unable to conceive for any reason (unexplained infertility, poor ovarian reserve, male factor etc.) despite one year of regular unprotected intercourse and tried IVF for the first time. For OS, 50 female patients received Pergoveris® (recombinant follitropin alfa and lutropin alfa), while 50 female patients received Gonal-f® (recombinant follitropin alfa). Antagonist protocol was applied to all patients and trigger was made with Beta hCG. All women's age, BMI,infertility etiology and duration, basal follicle stimulating hormone (FSH) value, and antral follicle count were recorded. Gonadotropin dose andinduction times for both groups and the number of oocytes collected, the number of metaphase-2 (M2) oocytes, the number of embryos formed, embryo grade, the number of frozen and transferred embryos and OHSS status were compared. Infertility causes and induction times were similar in the patient groups that received Gonal-f and Pergoveris (p>0.05). The dose of the drug used was higher in the Pergoveris group (p=0,029). The number of collected oocytes, M2 oocytes, and formed-frozen-transferred embryos were comparable for both groups (p>0.05). Embryos transferred on day 3 were higher in patients using Gonal-f, while embryos transferred on day 5 were similar for both groups (p=0.015; p>0.05). Both groups were similarin terms of side effects of live birth, twin pregnancy, abortion, ectopic pregnancy, chemical pregnancy and OHSS (p>0.05). While no embryosdeveloped in eight patients who received Pergoveris, all patients who received Gonal-f developed embryos. In patients who had OS with Gonal-f or Pergoveris drugs in IVF cycles, there is no difference in the number of oocytes collected, formed-transferred-frozen embryos, live birth rate, multiplepregnancy rate, or OHSS.
References
Choe J, Archer JS, Shanks AL. IVF. Up To Date. Indiana University. 2021.
Bilgic BE, Yayla Abide C, Ozkaya E, Kutlu T, Ayla S, Sanverdi I, et al. Role of Oocyte Morphological Abnormality Rates on the Embryo Development and Implantation. Gynecol Obstet Reprod Med. 2018;24(3):131-8.
Yılmaz N, Kahyaoğlu İ. Ovulasyon indüksiyonu ve kontrollü ovaryan hiperstimülasyona genel bakış. Jinekoloji Obsterik ve Neonatoloji Tıp Dergisi 2012; 36:150917.
Demirel A, Güven S. Agonists and antagonists in COH. In: Ovarian Stimulation Protocols. Editors; Allahbadia GN, Morimoto Y. Springer India, 2016.
Kahyaoğlu İ. Kontrollü ovaryan stimülasyonda kullanılan protokoller. Ankara Zekai Tahir Burak Kadın Hastalıkları ve Doğum. 2019.
Gardner DK, Weissman A, Howles CM, Shoham Z. Textbook of Assisted Reproductive Techniques, Fifth Edition; Volume 2: Clinical Perspectives. 2018.
Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT. Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous folliclestimulating hormone in patients with secondary amenorrhea. Fertil Steril. 1999;72(6):1118-20.
Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999;84(1):228- 32.
Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, Parmegiani L, Pelusi G, DeAloysio D. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002;8(6):543-57.
Balasch J, Vidal E, Penarrubia J, Casamitjana R, Carmona F, Creus M, Fabregues F, Vanrell JA. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod. 2001;16(8):1636-43.
Shoham Z.The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril. 2002;77(6):1170-7.
Mochtar MH, Danhof NA, Ayeleke RO, Van der Veen F, Van Wely M, Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles, Cochrane Database Syst Rev. 2017 May; 2017(5): CD005070.
Humaidan P, Chin W, Rogoff D, D'Hooghe T, Longobardi S, Hubbard J, Schertz J and on behalf of the ESPART Study Investigators. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum reprod (Oxford, England). March 2017.
Rahman A, Francomano D, Sagnella F, Lisi F, Manna C. The effect on clinical results of adding recombinant LH in late phase of ovarian stimulation of patients with repeated implantation failure: a pilot study. European review for medical and pharmacological sciences. 2017;21: 5485-5490.
Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, Copt S, Tarlatzis B. Recombinant human follicle-stimulating hormone(r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reproductıve Biology and Endokrinology. February 2014.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Infertility
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 